Home › Funds › Fidelity › Select Medical Technology and Devices Portfolio
Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007473
Ticker: FSMEX (C000020447)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 352 with, 3 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 94.1% | 339 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 2 items (0.6% of the 349 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Sartorius Stedim Biotech SA | 2026-03-24 | Approve Compensation Report of Corporate Officers | For | AGAINST — 7 of 13 Fidelity funds | For | — |
| Sartorius Stedim Biotech SA | 2026-03-24 | Approve Remuneration Policy of CEO | For | AGAINST — 7 of 13 Fidelity funds | For | — |
Download all 2 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 89.9% of this fund’s 355 such votes could be given a sector; the other 36 (10.1%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 225 | 3 | 1.3% |
| Industrials | 75 | 0 | 0.0% |
| Technology | 19 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 248 | 0 |
| Audit-related | 35 | 0 |
| Say-on-Pay | 32 | 0 |
| Compensation | 19 | 0 |
| Corporate Governance | 15 | 3 |
| Capital Structure | 6 | 0 |
| Extraordinary Transactions | 3 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Danaher Corporation | May 5, 2026 | $550M | 14 | 0 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $463M | 13 | 0 |
| Intuitive Surgical, Inc. | April 30, 2026 | $274M | 13 | 0 |
| Boston Scientific Corporation | April 30, 2026 | $245M | 17 | 1 |
| Edwards Lifesciences Corporation | May 7, 2026 | $244M | 12 | 0 |
| Abbott Laboratories | April 24, 2026 | $172M | 16 | 0 |
| Stryker Corporation | May 6, 2026 | $148M | 12 | 0 |
| IQVIA Holdings Inc. | April 23, 2026 | $128M | 13 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | Against | For |
| April 23, 2026 | IQVIA Holdings Inc. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | Against | For |
| May 13, 2026 | ICU Medical, Inc. | To approve, on an advisory basis, a stockholder proposal to establish a 10% stockholder special meeting right. Shareholder proposal | Against | For |
359 ballot items at 40 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Select Medical Technology and Devices Portfolio (FSMEX) voted at 40 shareholder meetings of 39 companies, on 359 ballot items in all. Where management made a recommendation, the fund followed it on 99.2% of the items and voted against it 3 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 3 shareholder proposals. It voted FOR the board's own proposals about as often as Fidelity's funds as a whole (94.1% against 94.1%). It voted differently from most Fidelity funds on 2 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.